This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
I
Tepkinly is licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation - further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
UK-EPCOR-250059 | February 2025
Tepkinly is licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation - further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
UK-EPCOR-250059 | February 2025
Previous
Next
UK-EPCOR-240219 | June 2024
Tepkinly is licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation - further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
UK-EPCOR-250059 | February 2025
Tepkinly is licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation - further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
UK-EPCOR-250059 | February 2025
TEP Talks series
A collection of short videos from UK experts on the potential impact of Tepkinly in the 3L+ R/R DLBCL setting.
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two of more lines of systemic therapy.1
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
Tepkinly has a conditional marketing authorisation - further data awaited.
1. Tepkinly SmPC.
UK-EPCOR-250051 | March 2025
Previous
Next
Downloadable Resources
Tepkinly dosing and administration guide
A digital guide to dosing and administration of Tepkinly. The guide also provides instructions on how to prepare and store Tepkinly, along with important safety information.
Tepkinly patient information booklet
A booklet for you to download and pass onto your patients who have been prescribed Tepkinly. It contains information that can be referred to throughout treatment, including understanding the Tepkinly treatment routine and possible side effects. This is for use in conjunction with the patient information leaflet.
Using Tepkinly
Tepkinly Preparation and Administration: The vial method
A guide to the dilution and preparation of the priming (0.16mg), intermediate (0.8mg) doses, and the preparation of the full dose (48mg) of Tepkinly for subcutaneous administration. View the video for a full run through on storage, handling and preparation of Tepkinly, indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly Mode of Action animation
The Tepkinly mechanism of action is explained in this video which shows how by binding simultaneously to CD3 on T cells and CD20 on B cells, epcoritamab forms an immune synapse – inducing cytokine release and T-cell–mediated killing of malignant CD20-expressing cells.1
Pharmacist Perspectives
Integrating Tepkinly into your service – pharmacist perspective
Watch Vaishali Dulobdas, Lead Haematology Pharmacist at the University Hospitals Birmingham NHS Foundation Trust, provide valuable learnings and insights from the integration of Tepkinly into her service, including considerations around dosing, aseptic unit process flow, capacity and staffing, as well as importance of providing multidisciplinary team training.
Embracing innovation – pharmacy perspectives on the rapidly evolving treatment landscape in R/R DLBCL and using bispecific antibodies
Join Advanced Clinical Pharmacist Asjad Yousif (Cardiff) to learn about the dynamic treatment landscape of relapsed/refractory DLBCL and the impact of using bispecific antibodies. The video focuses on how Tepkinly fits into treatment pathways, exploring topics such as dosing and side effects.
Expert Perspectives at Frontiers Live Event
Tepkinly and the bispecific innovation
Watch Dr David Lewis of University Hospitals Plymouth NHS Trust describe the mechanism of action of bispecific therapies and detail the key efficacy and safety data from the phase I/II single arm study in patients with highly refractory DLBCL that supports Tepkinly as a treatment option for patients with relapsed or refractory DLBCL after 2 or more lines of systemic therapy.
Integrating Tepkinly into your service – a Consultant Perspective
Tap in to practical pointers from Dr David Tucker of the Royal Cornwall Hospital NHS Trust, Truro, a haematologist with extensive experience with bispecific therapies. Learn how education and enthusiasm, together with planning, could support integration of Tepkinly into your DLBCL service.
Integrating Tepkinly into your service – CNS & Pharmacist Perspectives
Listen to haematology research nurse specialist Nicola Crosbie (Plymouth) and lead haematology pharmacist Vaishali Dulobdas (Birmingham) provide their learnings from integrating Tepkinly into their services. They emphasise the importance of planning, preparedness and providing education for both HCPs and patients.
Tepkinly in practice: a guide to using Tepkinly
Learn from Dr Kim Linton of the Christie in Manchester – one of the principal investigators involved in the pivotal phase I/II single arm study of Tepkinly as a treatment for patients with relapsed or refractory DLBCL after 2 or more lines of systemic therapy – and her experiences using this subcutaneous bispecific antibody in practice.
Practical Management from a Nurse Perspective
Navigating Bispecific Therapies: Overcoming CRS and ICANS Challenges
Watch Ruth Clout, Lead Nurse at The Christie NHS Foundation Trust, provide practical guidance on cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) recognition, grading, and management, as well as prophylactic steps to mitigate their risk, in patients treated with Tepkinly.
By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
Abbreviations
CNS=clinical nurse specialist; R/R=relapsed/refractory.
References
- Tepkinly Summary of Product Characteristics.
UK-EPCOR-250026. Date of preparation: February 2025.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
